You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Medtronic

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Patent: 9,340,528

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,340,528
Title:Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
Abstract: The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds. ##STR00001##
Inventor(s): Bader; Benjamin (Berlin, DE), Bomer; Ulf (Glienicke, DE), Ince; Stuart (Berlin, DE), Koppitz; Marcus (Berlin, DE), Lienau; Philip (Berlin, DE), Marquardt; Tobias (Berlin, DE), Nguyen; Duy (Berlin, DE), Prechtl; Stefan (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Wegscheid-Gerlach; Christof (Marburg, DE)
Assignee: BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)
Application Number:13/393,583
Patent Claims:see list of patent claims

Details for Patent 9,340,528

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2029-09-04 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2029-09-04 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2029-09-04 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2029-09-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
Express Scripts
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.